Treating elevated CSF secretion in IIH patients may be achieved through either serotonin to inhibit Na+–K+-ATPase pathway through the activation and phosphorylation of protein kinase C [33]; antisense thyroid transcription factor-1 oligodeoxynucleotide to reduce AQP1 mRNA and protein expression in the CP [34]; or acetazolamide and topiramate treatment [35] to decrease intracellular carbonic anhydrase CP epithelium [6]. Here, CP is linked to pseudotumor cerebri.